Compounds > adam ii
Page last updated: 2024-09-27

adam ii

Description

ADAM II: an alkenyldiarylmethane compound; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID393516
CHEMBL ID294840
SCHEMBL ID14041153
MeSH IDM0291093

Synonyms (25)

Synonym
alkenyldiarylmethanes (adam) 22
methyl 3,3-dichloro-4,4-dimethoxy-5,5-bis(methoxycarbonyl)-6,6-diphenylhexenoate
bdbm2753
methyl 3-chloro-5-{1-[3-chloro-4-methoxy-5-(methoxycarbonyl)phenyl]-6-methoxy-6-oxohex-1-en-1-yl}-2-methoxybenzoate
chembl294840 ,
nsc695574
204864-54-0
methyl 3-chloro-5-[1-(3-chloro-4-methoxy-5-methoxycarbonyl-phenyl)-6-methoxy-6-oxo-hex-1-enyl]-2-methoxy-benzoate
adam ii
methyl 3',3''-dichloro-4',4''-dimethoxy-5',5''-bis(methoxycarbonyl)-6,6-diphenylhexenoate
benzoic acid, 3,3'-(6-methoxy-6-oxo-1-hexenylidene)bis[5-chloro-6-methoxy-, dimethyl ester
1,3''-dicarbomethoxy-5',5''-dichloro-4',4''-dimethoxydiphenyl)-5-hexenoate
nsc-695574
methyl 3-chloro-5-[1-(3-chloro-4-methoxy-5-methoxycarbonylphenyl)-6-methoxy-6-oxohex-1-enyl]-2-methoxybenzoate
dimethyl 3,3'-(6-methoxy-6-oxohex-1-ene-1,1-diyl)bis(5-chloro-6-methoxybenzoate)
nsc 695574
unii-kxwjvsivfb
adam-ii
kxwjvsivfb ,
benzoic acid, 3,3'-(6-methoxy-6-oxo-1-hexenylidene)bis(5-chloro-6-methoxy-, dimethyl ester
SCHEMBL14041153
DTXSID00174457
3,3'-(6-methoxy-6-oxo-1-hexenylidene)bis(5-chloro-6-methoxy-, dimethyl ester, benzoic acid
3,3'-(6-methoxy-6-oxo-1-hexen-1-ylidene)bis(5-chloro-6-methoxy-, 1,1'-dimethyl ester, benzoic acid
AKOS030594689

Research Excerpts

Overview

ExcerptReference
"ADAM II is a non-nucleoside reverse transcriptase inhibitor, displaying an IC50 of 0.3 microM with poly(rC) oligo(dG) as the template/primer."( Casimiro-Garcia, A; Cushman, M; Rice, WG; Williamson, K, 1998)

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.62000.00060.91418.3200AID1795426; AID1795427; AID1795429; AID1795431
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.70000.00011.076810.0000AID197954; AID197957; AID198107; AID198415; AID199088; AID298059; AID317728; AID82960
Protease Human immunodeficiency virus 1IC50 (µMol)100.00000.00010.22487.3200AID162387
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (137)

Assay IDTitleYearJournalArticle
AID45005The compound is evaluated for the fold resistance.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46421The compound is evaluated for the activity against HIV-1 NL4-3, L100I mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID44999The compound is evaluated for the activity against HIV-1 IIIB, wild - type mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45002The compound is evaluated for the activity against calo ( calanolide resistant), T139I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46429The compound is evaluated for the inhibitory activity against HIV-1 IIIB, wild-type laboratory adapted strain in CEM-SS.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID83089Inhibition of cytopathic effect of HIV-1 strain wild type enzyme NL4-3 in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID125202The compound is evaluated for the inhibitory activity against HIV-1 Ba-L, monocyte-tropic in Mono/Mac cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID154774Antiviral activity against WEJO virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46380Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154773Antiviral activity against TEKI virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID317729Antiviral activity against HIV1RF infected in human CEM-SS cells2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID46425The compound is evaluated for the activity against HIV-1 NL4-3, V179D mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46417The compound is evaluated for the activity against HIV-1 NL4-3, 4XAZT/Y181C (AZT resistant) mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID154772Antiviral activity against SLKA virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46431The compound is evaluated for the fold resistance.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID154787Antiviral activity against subtype isolate F strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45695Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation Y188C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID298065Metabolic stability in rat plasma2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID46383Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45694Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation Y181C resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45689Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation L74V in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46081Ratio of CC50/EC50 was determined2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46377Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46382Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID155110The compound is evaluated for the inhibitory activity against HIV-1, clade D in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID105315Effective concentration required to inhibit cytopathicity of HIV-1(IIIB) in MT-4 cells2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID154785Antiviral activity against subtype isolate E strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154777Antiviral activity against subtype isolate A strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID317730Antiviral activity against HIV13B infected in human MT4 cells2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID155108The compound is evaluated for the inhibitory activity against HIV-1, clade B in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45173Concentration required for cytotoxicity against mock infected CEM-SS cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46418The compound is evaluated for the activity against HIV-1 NL4-3, A98G mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID317731Antiviral activity against HIV2ROD infected in human MT4 cells2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID162387The compound is evaluated for the inhibitory against HIV -1 protease, a 17% inhibition of HIV-1 protease was observed at a concentration of 100 uM1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID12678Half-life in rat plasma2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID45869Fold resistance of HIV-1 RT containing the specified mutation V108I in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45721Fold resistance of HIV-1 RT containing the specified mutation A98G in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46423The compound is evaluated for the activity against HIV-1 NL4-3, V106A mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46378Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID317732Cytotoxicity against human HIV1RF infected CEM-SS cells by MTT assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID45873Fold resistance of HIV-1 RT containing the specified mutation Y181C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID47659The compound is evaluated for the activity against 129/cost (costatolide resistant), V108I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID298063Cytotoxicity against human CEM-SS cells by MTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID154775Antiviral activity against multi drug resistant MDR 769 strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154779Antiviral activity against subtype isolate B strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45555Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation 4X resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID298061Antiviral activity against HIV1 3B in human MT4 cells by XTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID45692Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation V179D in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46979The compound is evaluated for the cytotoxic concentration for the mock-infected CEM cells1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID235026The compound is evaluated for the therapeutic index, which is the CC50 divided by the EC50.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46379Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46416The compound is evaluated for the activity against HIV-1 NL4-3, 4XAZT/L100I (AZT resistant) mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID235245Therapeutic index was determined for the compound as CC50/EC501999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46375Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID91428The compound is evaluated for the inhibitory against HIV -1 integrase. NI indicates no inhibition at 100 uM conc.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45875Fold resistance of HIV-1 RT containing the specified mutation Y181C resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155112The compound is evaluated for the inhibitory activity against HIV-1, clade F in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46374Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46427The compound is evaluated for the activity against HIV-1 NL4-3, Y188C mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45718Fold resistance of HIV-1 RT containing the specified mutation 4X resistant to AZT in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID44998The compound is evaluated for the activity against HEPT ((Hydroxyethoxy) methyl (phenylthio)thymine resistant), P236L mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID155107The compound is evaluated for the inhibitory activity against HIV-1, clade A in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45877Fold resistance of HIV-1 RT containing the specified mutation Y188C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID154781Antiviral activity against subtype isolate C strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID155113The compound is evaluated for the inhibitory activity against HIV-1 ROJO, wild-type clinical isolate in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID82960Compound was tested for the inhibition of HIV-1 reverse transcriptase1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID46415The compound is evaluated for the activity against HIV-1 NL4-3, 4XAZT (AZT resistant) mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46420The compound is evaluated for the activity against HIV-1 NL4-3, K103N mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID317728Inhibition of HIV1 reverse transcriptase2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID298060Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID46424The compound is evaluated for the activity against HIV-1 NL4-3, V108I mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID298062Antiviral activity against HIV2 ROD in human MT4 cells by XTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID45687Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation L100I in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155111The compound is evaluated for the inhibitory activity against HIV-1, clade E in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID198415The compound is evaluated for the inhibitory against HIV -1 reverse transcriptase with rAdT as the template primer.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45725Fold resistance of HIV-1 RT containing the specified mutation K103N in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45691Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation V108I in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID199088Inhibitory activity against HIV-1 Reverse Transcriptase with rCdG as the template primer2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID40034Antiviral activity against Ba-L monocyte tropic isolate strain in monocyte2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID298064Cytotoxicity against human MT4 cells by MTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID154783Antiviral activity against subtype isolate D strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46433The compound is evaluated for the fold resistance; S - Enhanced sensitivity1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45686Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation K103N in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID146804Inhibition of HIV-1 Nucleocapsid protein p7 (no inhibition at 25 uM)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46249Compound was tested for the prevention of cytopathic effect of HIV-1 RF in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID154771Antiviral activity against ROJO virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45000The compound is evaluated for the activity against OC (Oxathiin carboxanilide resistant), L100I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45688Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation L100I resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46083Compound was tested for cytotoxicity in uninfected CEM-SS cells1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID105317Effective concentration required to inhibit cytopathicity of HIV-2(ROD) in MT-4 cells2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID46430The compound is evaluated for the inhibitory activity against HIV-1 RF, wild-type laboratory adapted strain in CEM-SS.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID1331273Inhibition of HIV-1 reverse transcriptase assessed as reduction in [32P]GTP incorporation using poly(rC)/oligo(dG) as template/primer by beta counting method2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives.
AID47661The compound is evaluated for the activity against DPS ( Diphenyl sulfone resistant), Y181C mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45001The compound is evaluated for the activity against TSAO/cost (costatolide resistant), K101E mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45003The compound is evaluated for the activity against cost, Y188H mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46376Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154789Antiviral activity against subtype isolate G strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46432The compound is evaluated for the fold resistance; NC - No significant change in sensitivity1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45864Fold resistance of HIV-1 RT containing the specified mutation L74V in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID317734Inhibition of tubulin polymerization after 20 mins2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID298059Inhibition of HIV1 reverse transcriptase2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID46617Therapeutic index (CC50/EC50) was determined1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID125201The compound is evaluated for the inhibitory activity against HIV-1 ADA, monocyte-tropic in Mono/Mac cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45847Concentration inhibiting 50% of mock-infected CEM cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46426The compound is evaluated for the activity against HIV-1 NL4-3, Y181C mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45684Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation A98G in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45863Fold resistance of HIV-1 RT containing the specified mutation L100I resistant to AZT in CEM-SS cells; S=Enhanced sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID317733Cytotoxicity against mock-infected human MT4 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID4535150% inhibitory concentration for cytopathicity of HIV-1 RF in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID197954Inhibition of HIV-1 Reverse transcriptase using poly-(ra)-oligo(dt) as the template primer.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45867Fold resistance of HIV-1 RT containing the specified mutation V106A in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45690Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation V106A in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45693Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation Y181C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID197957Inhibition of HIV-1 Reverse transcriptase using poly-(rc)-oligo(dg) as the template primer.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155109The compound is evaluated for the inhibitory activity against HIV-1, clade C in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46384Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46385Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID104801Evaluated for cytotoxicity in mock-infected MT-4 cells2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID45697Inhibitory concentration for cytopathicity of HIV-1RF in CEM-SS cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45871Fold resistance of HIV-1 RT containing the specified mutation V179D in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155114The compound is evaluated for the inhibitory activity against HIV-1 TEKI, wild-type clinical isolate in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46261Inhibitory concentration for cytopathicity of HIV-1 in CEM-SS cells1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45004The compound is evaluated for the activity against thiazol (thiazolobenzimidazole resistant), T139I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45685Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation K101E in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46381Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154791Antiviral activity against subtype isolate O strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46419The compound is evaluated for the activity against HIV-1 NL4-3, K101E mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45861Fold resistance of HIV-1 RT containing the specified mutation L100I in CEM-SS cells; S=Enhanced sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID47660The compound is evaluated for the activity against 3TC, M184I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46422The compound is evaluated for the activity against HIV-1 NL4-3, L74V mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46428The compound is evaluated for the activity against HIV-1 NL4-3, wild - type mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID198107Inhibitory activity against human immunodeficiency virus (HIV) - 1 reverse transcriptase with rCdG as the template primer1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45723Fold resistance of HIV-1 RT containing the specified mutation K101E in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID1795429HIV-1 RT Assay from Article 10.1016/s0968-0896(01)00282-6: \\Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.\\2002Bioorganic & medicinal chemistry, Feb, Volume: 10, Issue:2
Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.
AID1795427HIV-1 RT Assay from Article 10.1021/jm010212m: \\The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibi2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1795431HIV-1 RT Assay from Article 10.1021/jm990343b: \\Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.\\1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID1795426HIV-1 RT Assay from Article 10.1021/jm9800595: \\New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.\\1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (33.33)18.2507
2000's5 (55.56)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
nevirapine[no description available]medium30cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine[no description available]medium30azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz[no description available]medium20acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
colchicine[no description available]medium10alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
fosbretabulin[no description available]medium10stilbenoid
ConditionIndicatedRelationship StrengthStudiesTrials